![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics and Safety of Boosted-Elvitegravir in Subjects with Hepatic Impairment
|
|
|
Reported by Jules Levin
13th HIV Clinical Workshop Apr 16-18 2012 Barcelona Spain
S Ramanathan, M Rhee, G Shen, J Custodio, and BP Kearney
Gilead Sciences, Inc., Foster City, CA, USA
![pharm1.gif](../images/052112/052112-2/pharm1.gif)
![pharm2.gif](../images/052112/052112-2/pharm2.gif)
![pharm3.gif](../images/052112/052112-2/pharm3.gif)
![pharm4.gif](../images/052112/052112-2/pharm4.gif)
![pharm5.gif](../images/052112/052112-2/pharm5.gif)
![pharm6.gif](../images/052112/052112-2/pharm6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|